» Articles » PMID: 36313320

Research Advances in Treatment Methods and Drug Development for Rare Diseases

Overview
Journal Front Pharmacol
Date 2022 Oct 31
PMID 36313320
Authors
Affiliations
Soon will be listed here.
Abstract

As the incidence of rare diseases increases each year, the total number of rare disease patients worldwide is nearly 400 million. Orphan medications are drugs used to treat rare diseases. Orphan drugs, however, are rare and patients often struggle to utilize them and expensive medications during treatment. Orphan drugs have been the focus of new drug research and development for both domestic and international pharmaceutical companies as a result of the substantial investment being made in the field of rare diseases. Clinical breakthroughs have been made in every field, from traditional antibodies and small molecule drugs to gene therapy, stem cell therapy and small nucleic acid drugs. We here review the therapeutic means of rare diseases and drug development of rare diseases to show the progress of treatment of rare diseases in order to provide a reference for clinical use and new drug development of rare diseases in China.

Citing Articles

Antisense oligonucleotides and their applications in rare neurological diseases.

McDowall S, Aung-Htut M, Wilton S, Li D Front Neurosci. 2024; 18:1414658.

PMID: 39376536 PMC: 11456401. DOI: 10.3389/fnins.2024.1414658.


Challenges for gene therapy in the financial sustainability of health systems: a scoping review.

Ossandon H, Armijo N, Vargas C, Repetto G, Espinoza M Orphanet J Rare Dis. 2024; 19(1):243.

PMID: 38915120 PMC: 11197217. DOI: 10.1186/s13023-024-03249-z.


Development of Essential Oil Delivery Systems by 'Click Chemistry' Methods: Possible Ways to Manage Duchenne Muscular Dystrophy.

Kaspute G, Arunagiri B, Alexander R, Ramanavicius A, Samukaite-Bubniene U Materials (Basel). 2023; 16(19).

PMID: 37834674 PMC: 10573547. DOI: 10.3390/ma16196537.


Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin.

Okuyama R Pharmaceutics. 2023; 15(7).

PMID: 37513981 PMC: 10386398. DOI: 10.3390/pharmaceutics15071794.


Development of orphan drugs for rare diseases.

Yoo H Clin Exp Pediatr. 2023; 67(7):315-327.

PMID: 37402468 PMC: 11222908. DOI: 10.3345/cep.2023.00535.

References
1.
Mays R, Deans R . Adult adherent cell therapy for ischemic stroke: clinical results and development experience using MultiStem. Transfusion. 2016; 56(4):6S-8S. DOI: 10.1111/trf.13562. View

2.
Mitchell P, Liew G, Gopinath B, Wong T . Age-related macular degeneration. Lancet. 2018; 392(10153):1147-1159. DOI: 10.1016/S0140-6736(18)31550-2. View

3.
Somaraju U, Tadepalli K . Hematopoietic stem cell transplantation for Gaucher disease. Cochrane Database Syst Rev. 2017; 10:CD006974. PMC: 6485517. DOI: 10.1002/14651858.CD006974.pub4. View

4.
Alessandrini M, Preynat-Seauve O, De Bruin K, Pepper M . Stem cell therapy for neurological disorders. S Afr Med J. 2019; 109(8b):70-77. DOI: 10.7196/SAMJ.2019.v109i8b.14009. View

5.
Barkau C, OReilly D, Eddington S, Damha M, Gagnon K . Small nucleic acids and the path to the clinic for anti-CRISPR. Biochem Pharmacol. 2021; 189:114492. PMC: 8725204. DOI: 10.1016/j.bcp.2021.114492. View